Latest Europe News

xReality Group delivered a standout Q3 FY26 with a 62% jump in cash receipts and a new Mixed Reality sale to the US Department of Defense, underpinning its growing Operator XR platform.

Vection Technologies has reported its third straight quarter of positive operating cash flow, driven by a $30 million Defence order book and a surge in AI contracts worth $4 million across multiple sectors.

Zinc of Ireland NL is set to reshape its zinc recovery and battery recycling prospects after signing to acquire Meclex's innovative hydrometallurgical technologies and launching a major drilling campaign at its Kildare project.

CurveBeam AI reported stable device orders but faces regulatory delays for FDA and China clearances, while securing a A$4 million investment from WEGO Orthopaedics and advancing clinical collaborations with robotic surgery systems.

Talga Group reported record anode production at its EVA plant and significant progress on its 5,000tpa Vittangi anode plant FEED study, alongside strategic partnerships and exploration breakthroughs.

European Metals Holdings has secured critical regulatory milestones for its Cinovec Lithium Project, submitting the full Environmental Impact Assessment and obtaining Regional Rezoning approval. The company also raised A$3.46 million to support ongoing development.

Altech Batteries has won conditional approval for a €46.11 million German government grant supporting its CERENERGY® Sodium-Chloride Solid-State battery project, while shifting its Silumina AnodesTM R&D operations to Germany to enhance efficiency and cut costs.

Orbital Corporation advances its UAV engine production and hybrid propulsion technology while managing a $0.5 million net cash outflow in Q1 2026, supported by a $43 million business pipeline and new international contracts.

Syntara Limited has raised A$10 million through a two-tranche placement and share purchase plan, backing its Phase 2b myelofibrosis trial and multiple clinical readouts following positive FDA feedback.

Starpharma has confirmed FDA alignment for its DEP® HER2 first-in-human phase 1 trial, with preparations underway for a mid-2026 start. The biotech also progressed strategic partnerships, published promising data with Genentech, and reported a $14.1 million cash balance alongside rising Viraleze™ sales.

GCM Corporation finalises exclusive rights to its Very High Density technology, launches its first commercial heat sink products, and expands global prototyping efforts targeting high-growth sectors including EV infrastructure and data centres.

Avecho Biotechnology has exceeded its Phase III CBD insomnia trial recruitment target by 16%, setting the stage for a more robust interim analysis scheduled for June 2026. The company’s commercial partnership with Sandoz AG and strengthened patent portfolio underpin its Australian market strategy.